Vitamin C Supplementation Shows Potential in Precancerous Blood Disorder Treatment
Phase 2 clinical trial suggests oral vitamin C may improve survival in early-stage blood cancer patients.
1Clinical Trial Overview
The phase 2 EVITA clinical trial investigated the impact of daily oral vitamin C on patients with precancerous blood disorders. Researchers enrolled 109 participants diagnosed with clonal cytopenia of undetermined significance or myelodysplastic syndrome. This randomized, double-blind, placebo-controlled study aimed to determine if correcting vitamin C deficiencies could improve patient outcomes.
2Methodology and Dosage
Participants were randomly assigned to receive either 1,000 mg of oral vitamin C or a placebo daily for one year. The study was conducted across four hospitals, including Copenhagen University Hospital and Keck Hospital. This rigorous design minimized bias, ensuring that neither patients nor clinical staff knew the treatment assignments until completion.
3Key Survival Findings
While vitamin C did not significantly alter the expansion rate of abnormal blood cells, exploratory analysis yielded positive results. Participants receiving the supplement showed a significantly higher likelihood of survival after approximately three years of follow-up compared to the placebo group. Researchers emphasize that these findings require verification through larger phase 3 trials.
4Biological Mechanisms Involved
Vitamin C supports the activity of the TET2 enzyme, which is critical for preventing cancerous growth by regulating gene activity. Mutations in TET2 are frequently observed in leukemia and related blood disorders. By restoring normal epigenetic function, vitamin C may help stabilize gene regulation and slow the progression of abnormal blood cells.
5Addressing Deficiency Prevalence
At the start of the EVITA trial, more than half of the enrolled participants exhibited insufficient vitamin C levels. Supplementation successfully normalized blood concentrations among those in the treatment group. This correction is significant because physicians currently have few options beyond monitoring patients with pre-leukemia conditions for signs of disease progression.
6Shift Toward Cancer Interception
The research reflects a growing medical emphasis on cancer interception, which involves intervening before the disease becomes established. By targeting biological changes that precede leukemia, scientists hope to provide an accessible, non-invasive treatment option. This approach is particularly relevant for older adults who may not be candidates for intensive stem cell transplants.
7Historical Research Context
Scientists have explored the role of vitamin C in cancer treatment for over seven decades with inconsistent results. Previous studies often focused on intravenous administration or solid tumors rather than precancerous blood conditions. The EVITA trial distinguishes itself by evaluating a standard oral dose in a controlled, prospective clinical setting for blood malignancies.
8Future Research Directions
These preliminary findings provide a foundation for larger, more expansive clinical studies to confirm the observed survival benefits. Researchers are currently analyzing trial data to better understand the specific biological processes involved. While not yet a definitive clinical recommendation, the study offers a promising, accessible strategy for managing high-risk blood disorders.